• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Genprex Inc.

    10/22/24 12:01:59 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNPX alert in real time by email
    SC 13G 1 j1022240sc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 0)*

     

    Genprex Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 PER SHARE
    (Title of Class of Securities)

     

      372446203  
      (CUSIP Number)  
     
    October 21,2024
    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      o Rule 13d-1(b)
         
      x Rule 13d-1(c)
         
      o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     Page 1 of 6 
     

     

    CUSIP No.  372446203
    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    MASAYA OTSUKA

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

    (a)☐

    (b)☐

    3

    SEC® USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    JAPAN

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    175,214Shares

    6

    SHARED VOTING POWER

     

    0 Shares

    7

    SOLE DISPOSITIVE POWER

     

    175,214Shares

    8

    SHARED DISPOSITIVE POWER

     

    0 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0Shares

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.76%

    12

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

     Page 2 of 6 
     

     

    Item 1(a). Name of Issuer:
       
       Genprex Inc.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
      

    1601 Trinity Street, Bldg. B, Suite3.322

    AUSTIN, TX, 78712

       
    Item 2(a). Name of Person Filing:
       
       MASAYA OTSUKA
       
    Item 2(b). Address of Principal Business Office or, if none, Residence:
         
      

    Yukarigaoka Miyanodai Haitsu #314

    1-3-1 Miyanodai, Sakura-shi,Chiba-ken,285-0857, JAPAN

       
    Item 2(c). Citizenship:
       
       JAPAN
       
    Item 2(d). Title of Class of Securities:
       
       Common Stock, par value $0.001 per share
       
    Item 2(e). CUSIP Number:  37244620

     

     Page 3 of 6 
     

     

    Item 3. If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      (a) o Broker or dealer registered under Section 15 of the Act;
      (b) o Bank as defined in Section 3(a)(6) of the Act;
      (c) o Insurance company as defined in Section 3(a)(19) of the Act;
      (d) o Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) o An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) o An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
      (g) o A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
      (j) o A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
      (k) o Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:      

     

    Item 4. Ownership.
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       (a) Amount Beneficially Owned: 175,214
       (b) Percent of Class: 6.76%
       (c) Number of shares as to which such person has:
          (i) sole power to vote or to direct the vote: 175,214
          (ii) shared power to vote or to direct the vote: 0
          (iii) sole power to dispose or to direct the disposition of: 175,214
          (iv) shared power to dispose or to direct the disposition of: 0

     

     Page 4 of 6 
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.
       
     Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
       Not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
       Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
       Not applicable.
       
    Item 9. Notice of Dissolution of Group.
       
       Not applicable.
       
    Item 10. Certification.
       
       By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect for the time being.

     

     Page 5 of 6 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: October 22,2024 MASAYA OTSUKA
       
       
      /s/ MASAYA OTSUKA  
      Name: MASAYA OTSUKA  
      Title: Individual  

     

     

    Page 6 of 6

     

     

     

    Get the next $GNPX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GNPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    National Securities initiated coverage on Genprex with a new price target

    National Securities initiated coverage of Genprex with a rating of Buy and set a new price target of $7.00

    1/26/21 7:48:53 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

    $2.7 million upfront with up to an additional $5.4 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants AUSTIN, Texas, Oct. 23, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into definitive agreements for the issuance and sale of 243,622 shares of common stock at a purchase price of $11.21 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered short-term warrants

    10/23/25 8:12:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

    Reqorsa® Gene Therapy is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Research Suggests that REQORSA May Be an Effective Treatment in Patients Progressing on Alectinib AUSTIN, Texas, Oct. 23, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present positive preclinical data at the upcoming 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 at the Hynes Convention Center in Boston

    10/23/25 7:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

    Reqorsa® Gene Therapy is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer AUSTIN, Texas, Oct. 14, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present positive preclinical data at the upcoming 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 22-26, 2025 at the Hynes Convention Center in Boston. The collaborators will present positive preclinical data from a study of Genprex's lead drug can

    10/14/25 7:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    SEC Filings

    View All

    Genprex Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Genprex, Inc. (0001595248) (Filer)

    10/24/25 8:26:43 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Genprex Inc.

    424B5 - Genprex, Inc. (0001595248) (Filer)

    10/24/25 8:26:09 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Genprex, Inc. (0001595248) (Filer)

    10/23/25 7:05:16 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Berger Mark Stanley covered exercise/tax liability with 4,500 shares, decreasing direct ownership by 20% to 17,971 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    7/1/25 5:52:13 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CEO and CFO Confer Ryan M. covered exercise/tax liability with 5,775 shares, decreasing direct ownership by 15% to 32,968 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    7/1/25 5:51:04 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Berger Mark Stanley covered exercise/tax liability with 585 shares, decreasing direct ownership by 3% to 22,471 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    2/19/25 8:01:36 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Leadership Updates

    Live Leadership Updates

    View All

    Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

    Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas, May 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the sudden passing of the Company's co-founder and previous Chairman Rodney Varner. Prior to his appointment as Chairman,

    5/13/24 8:31:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

    Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer AUSTIN, Texas, Aug. 22, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the appointment of Suzanne Thornton-Jones, Ph.D. as Senior Vice President, Regulatory Affairs. Dr. Thornton-Jones will leverage her regulatory expertise to guide and oversee the Company's regulatory submissions and strategy

    8/22/23 7:30:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Genprex Inc.

    SC 13G/A - Genprex, Inc. (0001595248) (Subject)

    10/24/24 12:23:37 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genprex Inc.

    SC 13G - Genprex, Inc. (0001595248) (Subject)

    10/22/24 12:01:59 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genprex Inc.

    SC 13G - Genprex, Inc. (0001595248) (Subject)

    10/3/24 10:09:50 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care